Microphysiological Drug-Testing Platform for Identifying Responses to Prodrug Treatment in Primary Leukemia

Furkan Gökçe(ETH Zurich), Mario M. Modena(ETH Zurich), Martina de Geus(ETH Zurich), Beat Bornhäuser(University Children's Hospital Zurich), Christian Lohasz(ETH Zurich), Alicia J. Kaestli(Whitehead Institute for Biomedical Research), Hans‐Michael Kaltenbach(ETH Zurich), Kasper Renggli(Vectura (Germany)), Andreas Hierlemann(ETH Zurich)
bioRxiv (Cold Spring Harbor Laboratory)
April 8, 2022
10.1101/2022.04.06.483760
Cited by 0

Related Papers

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
|Proceedings of the National Academy of Sciences|2011|1.1k
Nanoparticle Characterization: What to Measure?
|Advanced Materials|2019|469
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
|Journal of Clinical Investigation|2010|311
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2018|304